Author

T. Zenz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 8

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 8 Approach:experimental assay· 5 Assay:bulk RNA-seq· 4 Research Focus:drug response / drug discovery· 4 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Assay:DNA methylation· 3 Approach:statistical model· 3

Frequent Co-Authors

J. Lu· 6 shared P.-M. Bruch· 4 shared T. Roider· 4 shared W. Huber· 4 shared C. Kolb· 3 shared P. Dreger· 3 shared S. A. Herbst· 3 shared S. Dietrich· 3 shared

Activity by Year

2019-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersCancer Biology

J. Lu

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Proteogenomics refines the molecular classification of chronic lymphocytic leukemia

S. A. Herbst, M. Vesterlund, A. J. Helmboldt, R. Jafari, I. Siavelis, M. Stahl, E. Schitter, N. Liebers, B. Brinkmann, F. Czernilofsky, T. Roider, P.-M. Bruch, M. Iskar, A. Kittai, Y. Huang, , Hu

The paper performs a proteogenomic analysis of chronic lymphocytic leukemia, identifies a new poor-prognosis subgroup (ASB-CLL) through proteomic profiling, and links it to clinical outcomes.

bioRxiv · Mar 1, 2022Cancer Biology

Comparing the value of mono- versus coculture for high-throughput compound screening in hematological malignancies

S. A. Herbst, V. Kim, T. Roider, E. C. Schitter, P.-M. Bruch, N. Liebers, C. Kolb, M. Knoll, J. Lu, P. Dreger, C. Mueller-Tidow, T. Zenz, W. Huber, S. Dietrich

This study compares monoculture and stromal coculture for drug screening in hematological malignancies, finding that coculture reduces drug efficacy for many compounds but increases it for JAK inhibitors.

bioRxiv · Feb 18, 2022Cancer Biology

Combinatorial drug-microenvironment interaction mapping reveals cell-extrinsic drug resistance mechanisms and clinically relevant patient subgroups in CLL

P.-M. Bruch, H. A. R. Giles, C. Kolb, S. A. Herbst, T. Becirovic, T. Roider, J. Lu, S. Scheinost, L. Wagner, J. Huellein, I. Berest, M. Kriegsmann, K. Kriegsmann, C. Zgorzelski, P. Dreger, , S. Dietrich

This paper maps drug-microenvironment interactions in CLL to identify resistance mechanisms and patient subgroups, revealing how microenvironmental stimuli and genetic alterations influence drug response.

bioRxiv · Jul 23, 2021 · PreprintCancer Biology

NOTCH1 drives immune-escape mechanisms in B cell malignancies

M. Mangolini, A. Maiques-Diaz, S. Charalampopoulou, E. Gerhard-Hartmann, J. Bloehdorn, A. Moore, J. Lu, V. N. Roamio Franklin, C. S. Chilamakuri, I. Moutsoupoulos, A. Rosenwald, S. Stilgenbauer, T. Zenz, I. Mohorianu, C. DSantos, , I. Ringshausen

This study shows NOTCH1 mutations in B cell malignancies promote immune escape by upregulating PD-L1 and silencing HLA-class II, leading to poor clinical outcomes.

bioRxiv · Apr 10, 2021 · PreprintCancer Biology

SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues

M. M. Bühler, J. Lu, S. Scheinost, F. Nadeu, D. Roos-Weil, M. Hensel, T. Thavayogarajah, H. Moch, M. G. Manz, E. Haralambieva, E. Marques Maggio, S. Bea, E. Gine, E. Campo, O. A. Bernard, , T. Zenz

bioRxiv · Jun 9, 2020Cancer Biology

The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome

M. Duran-Ferrer, G. Clot, F. Nadeu, R. Beekman, T. Bauman, J. Nordlund, Y. Marincevic-Zuniga, G. Lonnerholm, A. Rivas, S. Martin, R. Ordonez, G. Castellano, M. Kulis, A. Queiros, L. Seung-Tae, , J. I. Martin-Subero

This study analyzes DNA methylation in B-cell tumors to show its relation to proliferative history and clinical outcomes, introducing a new mitotic clock for prognosis.

bioRxiv · Feb 6, 2020Cancer Biology

Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL

J. A. Wierzbinska, R. Toth, N. Ishaque, K. Rippe, J.-P. Mallm, L. Klett, D. Mertens, T. Zenz, T. Hielscher, M. Seifert, R. Kueppers, Y. Assenov, P. Lutsik, S. Stilgenbauer, P. M. Roessner, , D. B. Lipka

This study introduces Methyl-COOM, a method to identify cell-of-origin and CLL-specific epigenetic aberrations by analyzing DNA methylation patterns.

bioRxiv · Feb 4, 2020Cancer Biology

Dissecting intratumor heterogeneity of nodal B cell lymphomas on the transcriptional, genetic, and drug response level

T. Roider, J. Seufert, A. Uvarovskii, F. Frauhammer, M. Bordas, N. Abedpour, M. Stolarczyk, J.-P. Mallm, S. Rabe, P.-M. Bruch, H. Balke-Want, M. Hundemer, K. Rippe, B. Goeppert, M. Seiffert, , S. Dietrich

This study examines intratumor heterogeneity in B cell lymphomas by analyzing transcriptional, genetic, and drug response profiles across malignant subclones and immune cells.

bioRxiv · Dec 11, 2019Cancer Biology